Commerce fragmentation, geopolitical tensions, supply-chain realignments and protectionist insurance policies are weakening the previous assumptions of frictionless globalisation. For India, this disruption has opened a uncommon strategic window. As international locations search dependable, diversified and politically aligned manufacturing bases, India has a chance to maneuver from being a big participant in world commerce to a shaping drive inside it.
Click on right here to verify newest developments on Price range 2026
Among the many sectors able to appearing as a ‘energy lifter’ for India at this second, the pharmaceutical trade stands out. Few industries mix India’s present scale, world credibility, home developmental relevance and export potential as strongly as prescribed drugs. With the appropriate coverage thrust, the sector can concurrently strengthen financial resilience, elevate India’s export worth profile and deepen its integration into world healthcare provide chains, whereas additionally bestowing India with a quiet superpower.
Mega scale, however with out full worth
India at the moment is the third-largest pharmaceutical producer globally by quantity and ranks fourteenth by worth. Its medicines attain greater than 200 international locations, together with extremely regulated markets akin to the USA, Europe and Japan. The home pharmaceutical market, estimated at round $60 billion, is projected to greater than double to roughly $130 billion by 2030, pushed by rising incomes, demographic adjustments, expanded insurance coverage protection and rising prevalence of way of life illnesses.
India provides roughly 20 per cent of worldwide generic medicines and about 60 per cent of worldwide vaccine demand, a task that was dramatically underscored in the course of the COVID-19 pandemic. Pharmaceutical exports reached about $30.5 billion in FY 2024–25, rising at almost 10 per cent year-on-year, supported by a powerful manufacturing base and increasing worldwide outreach. The ecosystem now consists of round 800 medical gadget producers and an estimated 11,000 biotech start-ups, reflecting a widening innovation base past conventional formulations.
But the worth hole stays putting. Regardless of its world footprint, India accounts for less than about 3 per cent of whole world pharmaceutical export worth. The sector’s export basket remains to be dominated by low-margin generics, whereas high-value segments akin to biologics, novel drug discovery, superior medical units and proprietary platforms stay underdeveloped relative to world leaders. This imbalance limits revenue development, technological upgrading and strategic leverage.
Additionally Learn: Electronics is one guess India simply cannot underplay
Structural vulnerabilities beneath the energy
India’s pharmaceutical success has been constructed on price effectivity, chemistry expertise and regulatory familiarity, however it rests on a fragile supply-chain basis. Greater than 60 per cent of key uncooked supplies and energetic pharmaceutical substances (APIs) are imported, primarily from China. This dependence creates vulnerabilities in pricing, provide continuity and strategic autonomy, particularly in an period of weaponised commerce and geopolitical uncertainty. India has now launched minimal pricing on imports to protect Indian trade from low-priced imports.
High quality compliance has additionally emerged as a vital problem. Episodes involving contaminated cough syrups in abroad in addition to home markets have uncovered gaps in regulatory enforcement and manufacturing self-discipline amongst smaller corporations. Whereas India’s prime exporters meet the very best world requirements, uneven compliance throughout the lengthy tail of producers threatens reputational harm to the complete sector.
On the similar time, the trade faces rising pressures in its largest export market, the USA, which absorbs over one-third of India’s pharmaceutical exports. Pricing pressures, rising regulatory scrutiny and potential tariff actions have heightened the dangers of over-concentration. Whereas exports to the U.S. grew sharply in FY 2025, this dependence underscores the urgency of diversification.
Additionally Learn: What Sitharaman & Co can do to make medicines extra reasonably priced
Why pharma is usually a ‘energy lifter’ for India’s Economic system
Prescription drugs occupy a novel strategic place in India’s financial structure. Not like many manufacturing sectors, pharma combines excessive employment depth, export scalability and direct social affect. A stronger pharma sector lowers healthcare prices domestically, reduces import dependence for vital inputs and positions India as an indispensable companion in world well being safety.
Crucially, pharma has the potential to shift India’s export profile up the worth chain. Shifting from pure generics to advanced formulations, biosimilars, specialty medication and authentic analysis can considerably elevate export earnings with out proportionate will increase in quantity. That is particularly necessary as world demand more and more tilts in the direction of superior therapies, personalised medication and biologics.
The sector additionally aligns nicely with India’s broader industrial technique. Investments in prescribed drugs stimulate upstream chemical industries, biotechnology analysis, medical units, cold-chain logistics and medical analysis companies. In consequence, pharma development has multiplier results throughout manufacturing, companies and innovation ecosystems.
Govt is laying the groundwork
The federal government has already taken a number of steps to strengthen the pharmaceutical ecosystem. The Manufacturing-Linked Incentive (PLI) scheme for bulk medication and formulations has begun to draw funding into home API manufacturing, aiming to cut back exterior dependence and stabilise provide chains. Complementary measures such because the introduction of minimal import costs for choose inputs search to counter dumping and defend nascent home capacities.
Coverage initiatives just like the Ayushman Bharat Digital Mission have expanded healthcare entry and digitised well being knowledge, creating long-term demand for prescribed drugs whereas enabling data-driven analysis and medical trials. The Promotion of Analysis and Innovation in Pharma (PRIP) scheme displays a rising recognition that India should transfer past volume-led development in the direction of innovation-led competitiveness.
India’s emergence as a worldwide medical tourism hub additional reinforces the sector’s strategic relevance. Excessive-quality but reasonably priced remedy, supported by enhancements in hospital infrastructure and regulatory reforms, is deepening India’s function in cross-border healthcare companies.
What Price range 2026–27 can do to unlock the following section
The upcoming Price range gives a chance to transform incremental progress right into a structural leap. One vital space is analysis and growth. India’s pharmaceutical R&D spending stays nicely beneath world benchmarks. Budgetary help could be reoriented in the direction of long-term, affected person capital for drug discovery, biologics and platform applied sciences, fairly than short-term incentives tied solely to manufacturing volumes.
Strengthening regulatory capability must be one other precedence. A well-resourced, globally revered drug regulator will not be a value however a aggressive asset. Investments in regulatory infrastructure, inspector coaching and digital surveillance programs would assist guarantee uniform high quality compliance and defend India’s world fame.
Export diversification additionally deserves focused coverage consideration. Budgetary help for regulatory harmonisation, sooner market entry approvals and export financing for semi-regulated markets in Africa, Latin America and Southeast Asia can scale back dependence on the U.S. market. Commerce agreements must be leveraged extra explicitly to open pharmaceutical and medical gadget markets, together with via mutual recognition of requirements.
The Price range may play a task in integrating prescribed drugs with broader industrial coverage. Clusters combining API manufacturing, formulation models, biotech analysis and medical units can generate economies of scale and innovation density. Aligning pharma coverage with skilling initiatives, logistics upgrades and digital infrastructure would additional improve competitiveness.
India’s pharmaceutical sector has already demonstrated its means to ship at scale, below stress and with world affect. The following section is about depth fairly than breadth and worth fairly than quantity. In a world the place well being safety is more and more inseparable from financial and geopolitical safety, prescribed drugs provide India a uncommon probability to realize world leverage whereas boosting home self-reliance.
